QIAGEN Reports Full Q3 2026 Results
QIAGEN reported Q3 2026 net sales of $548 million, up 3% year-over-year and ahead of its outlook for 1-2% CER growth, with adjusted diluted EPS of $0.65 beating the outlook of at least $0.62 CER. Adjusted operating income margin expanded 0.8 points to 30.4%, helped by higher-margin consumables (91% of sales) and efficiency gains, while GAAP diluted EPS fell to $0.51 from $0.60.
Key figures
- Eps
- 0.51
- Revenue
- 548000000
- Guidance
- 2026 outlook suspended while the EQT Private Equity transaction is pending; no financial guidance provided
- Revenue Yoy
- 3%
- Adjusted eps
- 0.65
- Adjusted eps cer
- 0.65
- Operating income
- 132000000
- Adjusted operating income
- 167000000
- Consumables share of sales
- 91%
- Operating cash flow nine months
- 447000000
- Adjusted operating income margin
- 30.4%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.